There is currently no demonstrated patency advantage of a drug-eluting stent (DES) over bare metal stents (BMSs) for the treatment of marginal pathway disease of the femoropopliteal the component. In order to compare the patency of BMSs for the treatment of femoropopliteal artery wounds to the Eluvia DES (Boston Scientific, Marlborough, MA), a polymer-coated paclitaxel-eluting stent, the EMINENT study (Trial Comparing Eluvia Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery) was conducted. Blinded participation and outcome evaluation are features of the prospective, randomized trials, controlled, multicenter European study EMINENT. For measuring the research study used smart PLS software and generate result included descriptive statistic, correlation also that smart PLS Algorithm model between them. A decrease in Rutherford classification of ≥1 categories from baseline without repeat target lesion revascularization was considered sustained clinical improvement. Walking capacity and health-related quality of life were assessed. Since important meta-analyses of randomized controlled trials in interventional cardiology suggested that drug-eluting stents might reduce the rates of restenosis and reintervention, the use of active protecting technology in peripheral arterial interventions is one of the next steps in the treatment of arterial occlusive disease complying with coronary artery stenting. Overall result found that direct and significant relation in between Drug eluting stents and bare-metal stents in peripheral arterial diseases. Examining the literature on the current uses of drug-eluting stents in peripheral (lower limb, renal, and supra-aortic) settings, examining the financial ramifications, and offering recommendations for future therapeutic approaches in this area of research are our goals.